JCR Pharmaceuticals signed a license agreement with AstraZeneca’s rare disease unit Alexion to enable use of JCR’s JUST-AAV capsid technology in up to five genomic medicine programs. The deal includes an upfront payment and potential milestone and commercial success payments totaling up to $825 million. The JUST-AAV platform offers specialized adeno-associated virus vectors optimized for various tissues, including liver-sparing and brain-targeting variants. This marks the third collaboration between JCR and Alexion, reflecting a strong existing partnership. The financial terms have been incorporated into JCR’s current fiscal projections ending March 31, 2026.